Results 161 to 170 of about 1,882,276 (313)

Impact of Plasma p‐tau181 on Cognition, Motor Phenotypes, and Disease Course in ALS

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Phosphorylated tau181 (p‐tau181), an Alzheimer's disease biomarker, was recently evaluated in amyotrophic lateral sclerosis (ALS). We investigated plasma p‐tau181 in 202 ALS/ALS‐FTD patients and 94 healthy controls, assessing cognitive performance, motor function, and longitudinal dynamics.
Elisabeth Kasper   +25 more
wiley   +1 more source

Essential Clinically Applied Anatomy of the Peripheral Nervous System in the Limbs

open access: yes, 2015
Essential Clinically Applied Anatomy of the Peripheral Nervous System in the Limbs is designed to combine the salient points of the anatomy of the PNS with typical pathologies affecting the nerves of the upper and lower limbs.
Rea, Paul
core  

Editorial: Ion channels in the nervous system. [PDF]

open access: yesFront Cell Neurosci
Urrutia J, Villarroel A, Revuelta M.
europepmc   +1 more source

Peripheral Neutrophil Activation and Extracellular Trap Formation in Amyotrophic Lateral Sclerosis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
Markers of neutrophil activation are increased in plasma during ALS, and markers of NET formation associate with ALS survival. ABSTRACT Objectives Peripheral neutrophil levels in amyotrophic lateral sclerosis (ALS) inversely correlate with survival, suggesting a role for neutrophils in disease progression.
Lillia A. Baird   +9 more
wiley   +1 more source

Early Recognition of Treatment‐Responsive Rapidly Progressive Dementia: The Modified STAM3mP Score

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Early identification of patients with treatment‐responsive rapidly progressive dementia (RPD) is important as early treatment improves outcomes. The STAM3P score identifies treatment‐responsive RPD using “high risk” presenting features. We optimized performance by adding a time component (i.e., dementia within 3 months) and validated the ...
R. W. van Steenhoven   +16 more
wiley   +1 more source

Central nervous system toxicity of metallic nanoparticles

open access: yes, 2015
Xiaoli Feng,1 Aijie Chen,1 Yanli Zhang,1 Jianfeng Wang,2 Longquan Shao,1 Limin Wei2 1Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China; 2School and Hospital of Stomatology, Wenzhou Medical University, Wenzhou ...
Chen AJ   +5 more
core  

DHCR24 in cholesterol metabolism and diseases of the nervous system. [PDF]

open access: yesLipids Health Dis
Zhu H   +5 more
europepmc   +1 more source

Autonomic nervous system

open access: yesScholarpedia, 2008
Bill Blessing, Ian Gibbins
openaire   +1 more source

A 17 Year Old With Developmental Delay Presenting With Increasing Confusion and Imbalance

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Methylmalonic acidemia is an autosomal recessive genetic disorder primarily caused by defects in methylmalonyl‐CoA mutase and cobalamin (vitamin B12) metabolism. These defects disrupt the tricarboxylic acid cycle and oxidative phosphorylation, leading to the abnormal accumulation of metabolic products such as methylmalonic acid, propionic acid,
Wei Zhao, Yingli Zhang, Hongliang Zheng
wiley   +1 more source

Onasemnogene Abeparvovec in Patients With SMA: Interim Results of the RESTORE Registry in Japan

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective There are limited real‐world data regarding the safety and effectiveness of onasemnogene abeparvovec (OA; Zolgensma) infusion, a one‐time gene replacement therapy, for Japanese patients with spinal muscular atrophy (SMA). We aimed to improve understanding of the real‐world outcomes for OA in Japan.
Kayoko Saito   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy